Yahoo Finance • last month
* Instil Bio press release [https://seekingalpha.com/pr/20198987-instil-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:TIL [https://seekingalpha.com/symbol/TIL]): Q2 Non-GAAP EPS of -$3.24. * A... Full story
Yahoo Finance • last month
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC’s 2025 World Conference o... Full story
Yahoo Finance • 2 months ago
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with... Full story
Yahoo Finance • 3 months ago
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2... Full story
Yahoo Finance • 3 months ago
DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D.,... Full story
Yahoo Finance • 4 months ago
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman... Full story
Yahoo Finance • 4 months ago
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combinati... Full story
Yahoo Finance • 7 months ago
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 Enrollment of 1L NSCLC patients in trial of AXN-2510/IMM25... Full story
Yahoo Finance • 2 years ago
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with can... Full story
Yahoo Finance • 2 years ago
DALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with can... Full story
Yahoo Finance • 2 years ago
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facili... Full story
Yahoo Finance • 2 years ago
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023... Full story
Yahoo Finance • 2 years ago
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, March 31, 2023 (GLOBE NEWSWIRE)... Full story
Yahoo Finance • 3 years ago
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund returned 7.41% net compared to a 4... Full story
Yahoo Finance • 3 years ago
Company anticipates cash resources to provide runway beyond 2026 Initial clinical data from the ITIL-306 program expected in 2023 Instil is consolidating manufacturing and Phase 1 clinical trial of CoStAR-TIL™ to its operations in Manche... Full story
Yahoo Finance • 3 years ago
Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 With recent reprioritization of clinical programs and corporate restructuring, company... Full story
Yahoo Finance • 3 years ago
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instil Bio, Inc. (“Instil Bio” or the “Company”) (NASDAQ: TIL) on beh... Full story
Yahoo Finance • 3 years ago
NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PROG Holdings, Inc. (NYSE: PRG), Fox Corporation (NASDAQ: FOX, FOXA),... Full story
Yahoo Finance • 3 years ago
Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168 Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase 1 trial for NSCLC, ovarian, and renal cell carcinoma Reducing U.... Full story
Yahoo Finance • 3 years ago
NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ: FOX, FOXA), Instil Bio, Inc. (NASDAQ: TIL),... Full story